EUVIMEDEUVIMED entdecken
FallberichtOpen Access

A Case Report of Successful Use of Phenytoin/Fosphenytoin in a Pediatric Kidney Transplant Recipient With Nirmatrelvir/Ritonavir‐Induced Tacrolimus Allograft Injury

Jennifer L Hewlett iD, Selasie Goka, Uche Nwaogazie, Rachel Finkel, Lauren Galea, Sonya Lopez, Benjamin Laskin, Christopher LaRosa, Kevin J Downes iD, Sandra Amaral iD, Jonathan D Savant, Bernarda Viteri iD

Pediatric Transplantation · 2025

DOI: 10.1111/petr.70030 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Jennifer L Hewlett und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Phenytoin, Tacrolimus, Ritonavir. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Children's Hospital of Philadelphia Department of Pediatrics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Paxlovid, a fixed combination nirmatrelvir and ritonavir (NIM‐RTV), is a potent inhibitor of cytochrome P450 3A4 (CYP3A4) isoenzyme. It is approved for the treatment of mild to moderate COVID‐19 infections in patients at risk for serious infection. The metabolism of tacrolimus, a CYP3A4 substrate, is significantly reduced in those receiving NIM‐RTV. Coadministration of NIM‐RTV without tacrolimus dose reduction may result in toxicity. CYP3A4‐inducing medications, including phenytoin, fosphenytoin or rifampin, may reverse toxicity while achieving rapid clearance. Case Presentation A 14‐year‐old, 66.5 kg African American female with a history of chronic kidney disease stage 5 secondary to collapsing focal segmental glomerulosclerosis (FSGS) underwent an uncomplicated deceased donor kidney transplant at 12 years of age. Approximately 2.5 years after transplant, she tested positive for COVID‐19. NIM‐RTV was prescribed through a local pharmacy. She presented 3.5 days later with nausea, vomiting, fatigue, and oligo‐anuria with acute kidney injury (AKI) and creatinine of 2.6 mg/dL from baseline of 0.7 mg/dL. Tacrolimus level was > 60 ng/mL. Phenytoin/fosphenytoin was initiated to induce tacrolimus clearance due to sustained AKI and neurological risk. Within 36 h, her tacrolimus level was 38 ng/mLwith improved urine output. After 3 days, her tacrolimus level 11.9 ng/mL and serum creatinine was near baseline.

Conclusions

To our knowledge, this is the first report of a pediatric kidney transplant patient with tacrolimus toxicity secondary to NIM‐RTV therapy utilizing phenytoin/fosphenytoin to induce tacrolimus metabolism and prevent further toxicity. Heightened awareness of this interaction is paramount to reduce allograft injury and promote patient safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationPhenytoinTacrolimusRitonavirImmunosuppressive AgentsHumansFemaleAdolescentCOVID-19COVID-19 Drug TreatmentAcute Kidney Injury

Stichwörter der Autor:innen

COVID‐19Paxlovid (nirmatrelvir and ritonavir)case reportfosphenytoinkidney transplantpediatricphenytointacrolimus toxicity

Substanzen

PhenytoinTacrolimusRitonavirfosphenytoinImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Division of Nephrology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Jennifer L Hewlett, Kevin J Downes, Sandra Amaral, Bernarda Viteri

Förderung

  • NIDDK NIH HHS
  • Children's Hospital of Philadelphia Department of Pediatrics

Zitieren

APA

Hewlett, J. L., Goka, S., Nwaogazie, U., Finkel, R., Galea, L., Lopez, S., Laskin, B., LaRosa, C., Downes, K. J., Amaral, S., Savant, J. D., & Viteri, B. (2025). A Case Report of Successful Use of Phenytoin/Fosphenytoin in a Pediatric Kidney Transplant Recipient With Nirmatrelvir/Ritonavir‐Induced Tacrolimus Allograft Injury. Pediatric Transplantation. https://doi.org/10.1111/petr.70030

Vancouver

Hewlett JL, Goka S, Nwaogazie U, Finkel R, Galea L, Lopez S, et al. A Case Report of Successful Use of Phenytoin/Fosphenytoin in a Pediatric Kidney Transplant Recipient With Nirmatrelvir/Ritonavir‐Induced Tacrolimus Allograft Injury. Pediatric Transplantation. 2025. doi:10.1111/petr.70030

BibTeX
@article{Hewlett2025,
  author = {Hewlett, Jennifer L and Goka, Selasie and Nwaogazie, Uche and Finkel, Rachel and Galea, Lauren and Lopez, Sonya and Laskin, Benjamin and LaRosa, Christopher and Downes, Kevin J and Amaral, Sandra and Savant, Jonathan D and Viteri, Bernarda},
  title = {A Case Report of Successful Use of Phenytoin/Fosphenytoin in a Pediatric Kidney Transplant Recipient With Nirmatrelvir/Ritonavir‐Induced Tacrolimus Allograft Injury},
  journal = {Pediatric Transplantation},
  year = {2025},
  doi = {10.1111/petr.70030}
}
Kostenlos starten →